Biotech Startups

Exostemtech develops stem cell-derived exosome therapeutics and exosome platforms, including plant-derived exosomes, and offers research-use materials such as research stem cells and exosomes. The company operates in the biotechnology sector with a focus on exosome-based drug development.

1 investor

Endovision develops and manufactures medical devices including wound care, tissue regeneration, spinal surgery, sports medicine, gynecology, and laparoscopy products for hospitals and healthcare providers. The company, founded in 2013, focuses on domestic medical device innovation with capabilities in biotech products, 3D printing, and veterinary medical devices.

1 investor

NKMAX (엔케이젠바이오텍코리아 / NKGen Biotech Korea) is an immune cell therapy company focused on Natural Killer (NK) cells, developing NK-based immunotherapies, precision immune testing (NK cell activity tests), and immune health functional foods. Its products include NK cell activity diagnostic testing and the NK365 immune-support health supplement.

1 investor

Onegene develops multi-modality drugs using enzyme-mediated protein-protein conjugation technology to create multispecific therapeutics for complex diseases. Its pipeline includes a tetra-specific treatment for non-alcoholic steatohepatitis (NASH) and a tri-specific approach for T-cell-based immune activation in oncology.

1 investor

InnoCure Therapeutics develops Targeted Protein Degradation-based drugs using PROTAC and AUPTAC technologies to target pathogenic proteins that have been difficult to address with conventional small molecules. The company focuses on diseases with limited treatment options.

1 investor

Enhanced Bio (인핸스드바이오) is a biotechnology company developing novel therapeutics.

1 investor

EHLBIO develops stem cell therapeutics and works in regenerative medicine, including an autologous adipose-derived stem cell treatment (ADSTEM) for conditions such as atopic dermatitis. The company is based in South Korea and its therapies are progressing through clinical trials with the Korean Ministry of Food and Drug Safety.

1 investor

GLPharmTech is a pharmaceutical company that develops modified-release drug formulations, including Kabalin CR (pregabalin extended-release), for treating neuropathic pain conditions such as diabetic peripheral neuropathy and postherpetic neuralgia.

1 investor

Zincure is a biotech company developing treatments for brain disorders, focusing on acute conditions such as stroke and neurodegenerative diseases including ALS and multiple sclerosis. Founded in 2020, it conducts preclinical drug development in collaboration with hospitals and universities in Korea and the US.

1 investor

Kolon Pharmaceuticals develops pharmaceuticals and runs an oncology drug-discovery platform, using orthotopic transplant animal models and clinical translational research to identify anticancer targets, with a focus on pancreatic and ovarian cancer indications. The South Korean company co-develops new drugs with domestic and international biotech partners.

1 investor

Kolon TissueGene develops cell and gene therapies targeting musculoskeletal diseases and degenerative disorders. The company has built a proprietary platform over 20 years and aims to bring safe and effective treatments to improve pain and function for patients.

1 investor

Curacle develops first-in-class therapies aimed at restoring microvascular function in aging and chronic diseases, including small molecules via its SOLVADYS platform and biologics via its EAGLES platform. Its pipeline addresses conditions such as macular degeneration.

1 investor

Cureverse is a global biotech company that discovers novel small-molecule drugs based on its proprietary "Right Structure" concept, targeting intractable diseases including dementia, cancer, and inflammatory conditions. The company aims to provide sustainable therapeutic solutions with improved efficacy, safety, and drug-like properties for patients with difficult-to-treat neurological and systemic diseases.

1 investor

Therapex is a drug discovery company developing new therapeutics using in-silico molecular design and in-house medicinal chemistry and pharmacological evaluation systems. It has expertise in PROTAC-based new modalities that degrade disease-causing proteins.

1 investor

PeproMene Bio develops platform and products targeting BAFF-R, an innovative tumor antigen for treating B cell malignancies and autoimmune diseases. The company focuses on immune therapies to address tumor relapse caused by antigen loss in patients with unmet medical needs.

1 investor

Fugen Bio (퓨젠바이오) develops patented biomaterials, notably its CLEPS® ingredient, and sells consumer health and beauty products such as the Cellab biogenic essence and Cellna, a blood-sugar and insulin-resistance care product with clinically tested effects. The company operates in the biotech-based cosmetics and health supplement space, primarily in South Korea.

1 investor

FutureChem develops and manufactures radiopharmaceuticals for diagnostic imaging, particularly for detecting Alzheimer's disease, Parkinson's disease, and various cancers. The company operates GMP-compliant production facilities across multiple sites in South Korea to supply medical institutions.

1 investor

Igalphan is a Japanese research company focused on IgA antibodies, studying their potential for maintaining and improving health and preventing disease. The company works in collaboration with academic immunology research (referencing work from the University of Tokyo's immunology and infection control division).

1 investor

Innovacell searches globally for cell-based regenerative medicine candidates and develops and commercializes them into therapeutic products made from human cells, aiming to improve patients' health and quality of life. Its manufacturing technology originates from the GMP facility of Innovacell GmbH in Austria.

1 investor

Oncolys develops viral therapy drugs and treatments for cancer and severe viral infections, with a focus on oncolytic viruses and rare diseases. The company operates a hybrid business model combining licensing partnerships with pharmaceutical firms and direct commercialization of its own therapies.

1 investor

Carbgem (カーブジェン株式会社) is a Japanese company that applies generative AI, image AI, and cloud technology to build R&D and operational solutions, including drug discovery support, image and tissue analysis, quality control, medical document assistants, and diagnostic support. It serves life sciences, healthcare, consumer goods/distribution, manufacturing/infrastructure, and public/administrative sectors to address labor shortages, work standardization, and real-time decision-making.

1 investor

ClinCloud provides cloud-based solutions for collecting clinical trial data, aimed at improving the efficiency of data collection in drug development for pharmaceutical companies and research institutions. It also runs a CRO business covering data management and statistical analysis, and is based in Tokyo, Japan.

1 investor

Kolagen Pharma develops and sells pharmaceuticals, medical devices, and research reagents, and manufactures cosmetics, focusing on collagen-based biomaterials for regenerative medicine. Founded by university researchers in science and pharmacology, it is based within Kyoto University's medical research facilities in Japan.

1 investor

Cykinso uses data science to analyze the human microbiome, particularly gut flora, offering microbiome testing and clinical research support for consumers, athletes, corporate wellness programs, and food/materials companies. The company is based in Japan and operates services including at-home gut flora test kits and clinical trial support.

1 investor